Erasca (ERAS) Faces Securities Class Action After Stock Declines 48% on Drug Safety and IP Concerns-- HBSS

Erasca’s stock plunged $9.25 (-48%) after Revolution Medicines alleged ERAS-0015 patent infringement and a patient died roughly one month after receiving the drug, leading to an alleged $2.8B+ market-cap wipeout. The class action filed by Hagens Berman claims Erasca misled investors about ERAS-0015’s safety profile and the strength of its intellectual-property position, including prior statements about its in-licensed patent family. Disclosures on April 27, 2026 (a RevMed legal challenge letter and the patient fatality) appear to have driven the rapid repricing.

Analysis

ERAS is no longer being priced as a clinical readout story; it is being repriced as a credibility-and-financing story. In single-asset biotech, once the market starts questioning both IP moat and safety narrative at the same time, the equity value becomes hostage to dilution risk, trial-enrollment friction, and partner reluctance rather than to one data point. That usually means the first move understates the medium-term damage if the company cannot quickly re-establish independent proof on both patent position and adverse-event attribution.

The cleaner relative beneficiary is RVMD, but the effect is mostly defensive: any perception that ERAS overreached on comparisons should reinforce RVMD’s own narrative around differentiated chemistry and IP control. The second-order loser is the broader small-cap oncology complex, especially names trading on platform optionality and aggressive “best-in-class” language; those stocks can see multiple compression even without direct overlap because investors will apply a higher discount rate to unproven moats. If the reaction spills into XBI, the mechanism is not fundamental contagion but a higher cost of capital for the whole funding basket.

Key catalyst path: days for legal headlines and management rebuttal, 1-3 months for disclosure creep, amended complaints, and any investigator or safety follow-up, and 6-18 months for whether the asset remains financeable. The main falsifier is a clean independent safety narrative plus a narrowed IP dispute that does not threaten the program’s operating runway. Absent that, rallies are likely to be sold because the burden of proof has shifted from the plaintiffs to the company.

Key Decisions for Investors

• Short ERAS into any reflex bounce over the next 1-2 weeks; use strength to fade because the market is now trading financing risk, not just litigation risk. Cover if management delivers a credible third-party safety explanation and the patent dispute is resolved without impairing the program.
• Relative-value: long RVMD / short ERAS for 1-3 months. The pair isolates IP-quality and execution credibility; risk is that the entire pan-RAS category gets de-rated or RVMD becomes collateral damage from sector sentiment.
• Use ERAS put spreads or call spreads, 1-3 month tenor, rather than outright short if borrow is tight. This fits a binary-name where further downside can remain large but volatility will be elevated and gap risk is real.
• If the headline contamination spreads, buy XBI / short IBB as a tactical hedge only for 1-3 months. Small-cap biotech funding sentiment is more vulnerable than large-cap biotech to legal/safety credibility shocks.
• Set a watch item on any formal safety adjudication or patent-court filing over the next 30-60 days; if the company avoids a strong exculpatory disclosure by then, the odds favor another leg lower.